Fulgent Genetics/$FLGT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Fulgent Genetics
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Ticker
$FLGT
Sector
Primary listing
Employees
1,313
Headquarters
Website
Fulgent Genetics Metrics
BasicAdvanced
$697M
-
-$1.67
0.98
-
Price and volume
Market cap
$697M
Beta
0.98
52-week high
$24.64
52-week low
$14.57
Average daily volume
203K
Financial strength
Current ratio
6.01
Quick ratio
5.298
Long term debt to equity
0.531
Total debt to equity
0.713
Interest coverage (TTM)
-2,345.87%
Profitability
EBITDA (TTM)
-48.637
Gross margin (TTM)
40.04%
Net profit margin (TTM)
-16.83%
Operating margin (TTM)
-23.98%
Effective tax rate (TTM)
12.99%
Revenue per employee (TTM)
$230,000
Management effectiveness
Return on assets (TTM)
-3.74%
Return on equity (TTM)
-4.65%
Valuation
Price to revenue (TTM)
2.3
Price to book
0.63
Price to tangible book (TTM)
0.72
Price to free cash flow (TTM)
-11.632
Free cash flow yield (TTM)
-8.60%
Free cash flow per share (TTM)
-1.958
Growth
Revenue change (TTM)
4.31%
Earnings per share change (TTM)
-69.49%
3-year revenue growth (CAGR)
-31.05%
3-year earnings per share growth (CAGR)
-49.03%
What the Analysts think about Fulgent Genetics
Analyst ratings (Buy, Hold, Sell) for Fulgent Genetics stock.
Bulls say / Bears say
Fulgent’s Q2 2025 revenue of $81.8 million beat the Zacks Consensus Estimate by 7.8%, rising 16% year over year and supporting a raised full-year core revenue outlook of $320 million. (Nasdaq)
The company ended Q2 2025 with $777.5 million in cash, cash equivalents, restricted cash, and marketable securities, strengthening its balance sheet to fund its laboratory services expansion and therapeutic pipeline. (Business Wire)
Preliminary Phase 2 data shared at ESMO 2025 revealed that FID-007 plus cetuximab achieved a 51% overall response rate and median progression-free survival of 7.8 months, compared to 2.3 months historically in R/M HNSCC, showing notable clinical progress. (BioSpace)
Despite 16% revenue growth, Fulgent reported a GAAP net loss of $19.0 million, or $0.62 per share, in Q2 2025, highlighting persistent unprofitability even with higher revenues. (Business Wire)
Fulgent’s operations over the last twelve months ending Q2 2025 generated negative operating cash flow of $25 million, emphasizing ongoing cash burn related to expansion and R&D investments. (Investing.com)
Non-GAAP operating expenses increased to $43.9 million in Q2 2025 from $37.4 million in Q1 2025, squeezing margins as R&D and sales/marketing spending accelerated. (TipRanks)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2025.
Fulgent Genetics Financial Performance
Revenues and expenses
Fulgent Genetics Earnings Performance
Company profitability
Fulgent Genetics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fulgent Genetics stock?
Fulgent Genetics (FLGT) has a market cap of $697M as of November 07, 2025.
What is the P/E ratio for Fulgent Genetics stock?
The price to earnings (P/E) ratio for Fulgent Genetics (FLGT) stock is 0 as of November 07, 2025.
Does Fulgent Genetics stock pay dividends?
No, Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next Fulgent Genetics dividend payment date?
Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulgent Genetics?
Fulgent Genetics (FLGT) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.